Skip to main content
SpringerLink
Log in

Nicotine

  • Chapter
  • First Online:
Addiction Medicine

  • 5402 Accesses

Abstract

Nicotine is the most studied psychoactive component of tobacco, the use of which is the leading preventable cause of many diseases and deaths. Nicotine is highly addictive and thus strongly contributes to the effects of long-term tobacco use. Smoking cigarettes is a very fast and effective tool for nicotine delivery and nicotine dependence is a multifaceted syndrome consisting of biological, behavioral, and cognitive components. Therefore, the treatment of nicotine dependence often requires an integrated approach that includes behavioral and motivational therapy in addition to medication. Nicotine replacement therapies were the main pharmacologic option for treatment of nicotine dependence until the early 1990s, when bupropion became the first non–nicotine-based treatment option. In 2006, varenicline was approved by the United States Food and Drug Administration as a smoking cessation therapy. While these medications differ in their mechanism of action and efficacy, each has its place in the treatment of tobacco and nicotine dependence, and for some individuals, a combination of agents may be required to achieve abstinence from smoking.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC

    Google Scholar 

  2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, Text Revision. American Psychiatric Association, Washington, DC

    Google Scholar 

  3. Amos CI, Wu X, Broderick P et al (2009) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40:616–622

    Article  CAS  Google Scholar 

  4. Anda RF, Williamson DF, Escobedo LG et al (1990) Depression and the dynamics of smoking: a national perspective. JAMA 264:1541–1545

    Article  PubMed  CAS  Google Scholar 

  5. Aron AR, Robbins TW, Poldrack RA (2004) Inhibition and the right inferior frontal cortex. Trends Cogn Sci 8:170–177

    Article  PubMed  Google Scholar 

  6. Ascher JA, Cole JO, Colin JN et al (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395–401

    PubMed  CAS  Google Scholar 

  7. Bachmann MF, Rohrer UH, Kundig TM et al (1993) The influence of antigen organization on B cell responsiveness. Science 262:1448–1451

    Article  PubMed  CAS  Google Scholar 

  8. Baker TB, Piper ME, McCarthy DE et al (2004) Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychological Rev 111:33–51

    Article  Google Scholar 

  9. Barkley RA (1997) Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121:65–94

    Article  PubMed  CAS  Google Scholar 

  10. Barkley RA, Fischer M, Edelbrock CS et al (1990) The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29:546–557

    Article  PubMed  CAS  Google Scholar 

  11. Batel P, Pessione F, Maitre C et al (1995) Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 90:977–980

    Article  PubMed  CAS  Google Scholar 

  12. Beckham JC (1999) Smoking and anxiety in combat veterans with chronic posttraumatic stress disorder: a review. J Psychoactive Drugs 31:103–110

    Article  PubMed  CAS  Google Scholar 

  13. Beitchman JH, Douglas L, Wilson B et al (1999) Adolescent substance use disorders: findings from a 14-year follow-up of speech/language-impaired and control children. J Clin Child Psychol 28:312–321

    Article  PubMed  CAS  Google Scholar 

  14. Benowitz NL (1996) Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 36:597–613

    Article  PubMed  CAS  Google Scholar 

  15. Benowitz NL (2008) Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med 121(4 Suppl 1):S3–10

    Article  PubMed  CAS  Google Scholar 

  16. Bergen AW, Korczak JF, Weissbecker KA et al (1999) A genome-wide search for loci contributing to smoking and alcoholism. Genet Epidemiol 17(Suppl 1):S55–S60

    PubMed  Google Scholar 

  17. Berrettini WH, Wileyto EP, Epstein L et al (2007) Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 61:111–118

    Article  PubMed  CAS  Google Scholar 

  18. Berrettini W, Yuan X, Tozzi F et al (2008) Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 13:368–373

    Article  PubMed  CAS  Google Scholar 

  19. Bierut LJ, Madden PAF, Breslau N et al (2006) Novel genes identified in a high density genome wide association study for nicotine dependence. Hum Mol Genet 16:24–35

    Article  PubMed  CAS  Google Scholar 

  20. Bierut LJ, Stitzel JA, Wang JC et al (2008) Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 165:1163–1171

    Article  PubMed  Google Scholar 

  21. Bolliger CT, Zellweger JP, Danielsson T et al (2000) Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ 321:329–333

    Article  PubMed  CAS  Google Scholar 

  22. Borland BL, Heckman HK (1976) Hyperactive boys and their brothers. A 25-year follow-up study. Arch Gen Psychiatry 33:669–675

    Article  PubMed  CAS  Google Scholar 

  23. Borrelli B, Niaura R, Keuthen NJ et al (1996) Development of major depressive disorder during smoking-cessation treatment. J Clin Psychiatry 57:534–538

    Article  PubMed  CAS  Google Scholar 

  24. Botvinick MM, Braver TS, Barch DM et al (2001) Conflict monitoring and cognitive control. Psychol Rev 108:624–652

    Article  PubMed  CAS  Google Scholar 

  25. Brandon TH, Tiffany ST, Obremski KM et al (1990) Postcessation cigarette use: the process of relapse. Addict Behav 15:105–114

    Article  PubMed  CAS  Google Scholar 

  26. Breslau N (1995) Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 25:95–101

    Article  PubMed  CAS  Google Scholar 

  27. Breslau N, Klein DF (1999) Smoking and panic attacks: an epidemiologic investigation. Arch Gen Psychiatry 56:1141–1147

    Article  PubMed  CAS  Google Scholar 

  28. Breslau N, Kilbey MM, Andreski P (1991) Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 48:1069–1074

    Article  PubMed  CAS  Google Scholar 

  29. Breslau N, Kilbey MM, Andreski P (1993) Nicotine dependence and major depression: new evidence from a prospective investigation. Arch Gen Psychiatry 50:31–35

    Article  PubMed  CAS  Google Scholar 

  30. Breslau N, Peterson EL, Schultz LR et al (1998) Major depression and stages of smoking: a longitudinal investigation. Arch Gen Psychiatry 55:161–166

    Article  PubMed  CAS  Google Scholar 

  31. Breslau N, Johnson EO, Hiripi E et al (2001) Nicotine dependence in the United States: prevalence, trends, and smoking persistence. Arch Gen Psychiatry 58:810–816

    Article  PubMed  CAS  Google Scholar 

  32. Brown DC (1996) Smoking cessation in pregnancy. Can Fam Physician 42:102–105

    PubMed  CAS  Google Scholar 

  33. Brown RA, Kahler CW, Niaura R et al (2001) Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol 69:471–480

    Article  PubMed  CAS  Google Scholar 

  34. Brown RA, Niaura R, Lloyd-Richardson EE et al (2007) Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 9:721–730

    Article  PubMed  CAS  Google Scholar 

  35. Burgess ES, Kahler CW, Niaura R et al (2002) Patterns of change in depressive symptoms during smoking cessation: who’s at risk for relapse? J Consult Clin Psychol 70:356–361

    Article  PubMed  Google Scholar 

  36. Cappelleri JC, Baker CL, Bushmakin AG et al (2006) Effects of varenicline on craving and withdrawal symptoms. Presentation at the 12th annual meeting of the Society for Research on Nicotine and Tobacco

    Google Scholar 

  37. Carmelli D, Swan GE, Robinette D et al (1992) Genetic influence on smoking—a study of male twins. N Engl J Med 327:829–833

    Article  PubMed  CAS  Google Scholar 

  38. Carr LA, Basham JK, York BK et al (1992) Inihibition of uptake of 1-methyl-4-phenylpyridinium ion and dopamine in striatal synaptosomes by tobacco smoke components. Eur J Pharmacol 215:285–287

    Article  PubMed  CAS  Google Scholar 

  39. Carter BL, Long TY, Cinciripini PM (2004) A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res 6:221–227

    Article  PubMed  CAS  Google Scholar 

  40. Celtic Pharmaceutical Holdings LP (2006) News release: http://www.celticpharma.com/theportfolio/tanic.html, Accessed June 2010

  41. Centers for Disease Control and Prevention (2005) Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. MMWR Morb Mortal Wkly Rep 54:625–628

    Google Scholar 

  42. Centers for Disease Control and Prevention (2007) Cigarette smoking among adults, United States, 2007. MMWR Morb Mortal Wkly Rep 56/44:1157–1161

    Google Scholar 

  43. Centers for Disease Control and Prevention (2008) Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000–2004. MMWR Morb Mortal Wkly Rep 57:1226–1228

    Google Scholar 

  44. Chambers RA, Taylor JR, Potenza MN (2003) Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 160:1041–1052

    Article  PubMed  Google Scholar 

  45. Cinciripini PM, Wetter DW, Fouladi RT et al (2003) The effects of depressed mood on smoking cessation: mediation by post-cessation self-efficacy. J Consult Clin Psychol 71:292–301

    Article  PubMed  Google Scholar 

  46. Cinciripini PM, Wetter DW, Tomlinson GE et al (2004) The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 6:229–239

    Article  PubMed  CAS  Google Scholar 

  47. Cinciripini PM, Tsoh JT, Wetter DW et al (2005) Combined effects of venlafaxine, nicotine replacement & brief counseling on smoking cessation. Exp Clin Psychopharmacology 13:282–292

    Article  Google Scholar 

  48. Clayton AH (2007) Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert Opin Pharmacother 8:457–466

    Article  PubMed  CAS  Google Scholar 

  49. Clayton AH, Pradko JF, Croft HA et al (2002) Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63:357–366

    Article  PubMed  Google Scholar 

  50. Coe JW, Brooks PR, Vetelino MG et al (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477

    Article  PubMed  CAS  Google Scholar 

  51. Cohen C, Kodas E, Griebel G (2005) CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 81:387–395

    Article  PubMed  CAS  Google Scholar 

  52. Conti DV, Lee W, Li D et al (2008) Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 17:2834–2848

    Article  PubMed  CAS  Google Scholar 

  53. Covey LS, Glassman AH (1991) A meta-analysis of double-blind placebo controlled trials of clonidine for smoking cessation. Br J Addict 86:991–998

    Article  PubMed  CAS  Google Scholar 

  54. Covey LS, Hughes DC, Glassman AH (1994) Ever-smoking, quitting, and psychiatric disorders: evidence from the Durham, North Carolina, epidemiologic catchment area. Tob Control 3:222–227

    Article  Google Scholar 

  55. Curtin JJ, McCarthy DE, Piper ME et al (2006) Implicit and explicit drug motivational processes: a model of boundary conditions. In: Wiers RW, Stacy AW (eds) Handbook of implicit cognition and addiction. Sage, Thousand Oaks, CA

    Google Scholar 

  56. Damaj MI, Carroll FI, Eaton JB et al (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675–682

    Article  PubMed  CAS  Google Scholar 

  57. David SP, Brown RA, Papandonatos GD et al (2007) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9:821–833

    Article  PubMed  CAS  Google Scholar 

  58. David SP, Munafo MR, Murphy MF et al (2007) The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob Res 9:225–231

    Article  PubMed  CAS  Google Scholar 

  59. David SP, Strong DR, Munafo MR et al. (2007) Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 9(12):1251–1257.

    Article  PubMed  CAS  Google Scholar 

  60. David SP, Munafo MR, Murphy MF et al (2008) Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 8:122–128

    Article  PubMed  CAS  Google Scholar 

  61. Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393:295–314

    Article  PubMed  Google Scholar 

  62. Duggirala R, Almasy L, Blangero J (1999) Smoking behavior is under the influence of a major quantitative trait locus on human chromosome 5q. Genet Epidemiol 17(Suppl 1):S139-S144

    PubMed  Google Scholar 

  63. Epstein JN, Conners CK, Erhardt D et al (1997) Asymmetrical hemispheric control of visual-spatial attention in adults with attention deficit hyperactivity disorder. Neuropsychology 11:467–473

    Article  PubMed  CAS  Google Scholar 

  64. Etter JF (2006) Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 166:1553–1559

    Article  PubMed  CAS  Google Scholar 

  65. Etter JF, Laszlo E, Zellweger JP et al (2002) Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol 22:487–495

    Article  PubMed  CAS  Google Scholar 

  66. Evins AE, Cather C, Deckersbach T et al (2005) A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 25:218–225

    Article  PubMed  CAS  Google Scholar 

  67. Fagerström KO, Tejding LR, Ake W et al (1997) Aiding reduction of smoking with nicotine replacement medications. A strategy for the hopeless? Tob Control 6:311–316

    Article  Google Scholar 

  68. Faraone SV, Biederman J (2002) Efficacy of adderall for attention-deficit/hyperactivity disorder: a meta-analysis. J Atten Disord 6:69–75

    Article  PubMed  CAS  Google Scholar 

  69. Fiore MC, Jaen CR, Baker TB et al (2008) Treating tobacco use and dependence: 2008 update, clinical practice guideline. U.S. Department of Health and Human Services. Public Health Service, Rockville, MD

    Google Scholar 

  70. Gelernter J, Yu Y, Weiss R et al (2006) Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum Mol Genet 15:3498–3507

    Article  PubMed  CAS  Google Scholar 

  71. George TP, O’Malley SS (2004) Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25:42–48

    Article  PubMed  CAS  Google Scholar 

  72. Ginsberg D, Hall SM, Reus VI et al (1995) Mood and depression diagnosis in smoking cessation. Exper Clin Psychopharmacol 3:389–395

    Article  Google Scholar 

  73. Glassman AH, Stetner F, Walsh BT et al (1988) Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 259:2863–2866

    Article  PubMed  CAS  Google Scholar 

  74. Glassman AH, Helzer JE, Covey LS et al (1990) Smoking, smoking cessation, and major depression. JAMA 264:1546–1549

    Article  PubMed  CAS  Google Scholar 

  75. Glover ED, Laflin MT, Schuh KJ et al (2007) A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction 102:795–802

    Article  PubMed  Google Scholar 

  76. Gonzales D, Rennard SI, Nides M et al (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55

    Article  PubMed  CAS  Google Scholar 

  77. Gonzales DH, Rennard SI, Billing CB et al (2006) A pooled analysis of varenicline, an alpha 4 beta 2 nicotinic receptor partial agonist vs. bupropion, and placebo, for smoking cessation. Presented at the 12th annual meeting of the society for research on nicotine and tobacco, February 2006, Orlando, FL, Abstract PA9–2

    Google Scholar 

  78. Gourlay SG, Stead LF, Benowitz NL (2004) Clonidine for smoking cessation. Cochrane Database Syst Rev (3):CD000058

    Google Scholar 

  79. Grant BF, Hasin DS, Chou SP (2004) Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 61:1107–1115

    Article  PubMed  Google Scholar 

  80. Hall SM, Sees KL, Munoz RF et al (1996) Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. J Consult Clin Psychol 64:1003–1009

    Article  PubMed  CAS  Google Scholar 

  81. Hall SM, Humfleet GL, Reus VI et al (2002) Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 59:930–936

    Article  PubMed  CAS  Google Scholar 

  82. Hartsough CS, Lambert NM (1987) Pattern and progression of drug use among hyperactives and controls: a prospective short-term longitudinal study. J Child Psychol Psychiatry 28:543–553

    Article  PubMed  CAS  Google Scholar 

  83. Heatherton TF, Kozlowski LT, Frecker RC et al (1991) The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 86:1119–1127

    Article  PubMed  CAS  Google Scholar 

  84. Hecht SS (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3:733–744

    Article  PubMed  CAS  Google Scholar 

  85. Hertzberg MA, Moore SD, Feldman ME et al (2001) A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol 21:94–98

    Article  PubMed  CAS  Google Scholar 

  86. Hieda Y, Keyler DE, Vandevoort JT et al (1997) Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 283:1076–1081

    PubMed  CAS  Google Scholar 

  87. Hitsman B, Borelli B, McChargue DE et al (2003) History of depression and smoking cessation outcome: a meta-analysis J Consult Cinical Psychol 71:657–663

    Article  Google Scholar 

  88. Holroyd CB, Coles MGH (2002) The neural basis of human error processing: reinforcement learning, dopamine, and the error-related negativity. Psychol Rev 109:679–709

    Article  PubMed  Google Scholar 

  89. Huang W, Payne TJ, Ma JZ et al (2009) Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. Neuropsychopharmacology 34:319–330

    Article  PubMed  CAS  Google Scholar 

  90. Hughes JR, Stead LF, Lancaster T (2005) Nortriptyline for smoking cessation: a review. Nicotine Tob Res 7:491–499

    Article  PubMed  CAS  Google Scholar 

  91. Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev 1:CD000031

    PubMed  Google Scholar 

  92. Hung RJ, McKay JD, Gaborieau V et al (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452:633–637

    Article  PubMed  CAS  Google Scholar 

  93. Hurt RD, Sachs DPL, Glover ED et al (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202

    Article  PubMed  CAS  Google Scholar 

  94. Hutchison KE, Allen DL, Filbey FM et al (2007) CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 64:1078–1086

    Article  PubMed  CAS  Google Scholar 

  95. Izenwasser S, Cox BM (1992) Inhibition of dopamine uptake by cocaine and nicotine: tolerance to chronic treatments. Brain Res 573:119–125

    Article  PubMed  CAS  Google Scholar 

  96. Johnson EO, Rhee SH, Chase GA et al (2004) Comorbidity of depression with levels of smoking: an exploration of the shared familial risk hypothesis. Nicotine Tob Res 6:1029–1038

    Article  PubMed  Google Scholar 

  97. Johnson RA, Hoffmann JP (2000) Adolescent cigarette smoking in U.S. racial/ethnic subgroups: findings from the national education longitudinal study. J Health Soc Behav 41:392–407

    Article  PubMed  CAS  Google Scholar 

  98. Johnston LD, O’Malley PM, Bachman JG et al (2008) Monitoring the Future national results on adolescent drug use: overview of key findings, 2007 (NIH Publication No. [to be assigned]). National Institute on Drug Abuse, Bethesda, MD

    Google Scholar 

  99. Johnstone EC, Yudkin PL, Hey K et al (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14:83–90

    Article  PubMed  CAS  Google Scholar 

  100. Jorenby DE, Leischow SJ, Nides MA et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691

    Article  PubMed  CAS  Google Scholar 

  101. Jorenby DE, Hays JT, Rigotti NA et al (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63

    Article  PubMed  CAS  Google Scholar 

  102. Karam-Hage M, Cinciripini PM (2007) Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists. Curr Oncol Rep 9/6:509–516

    Article  Google Scholar 

  103. Kendler KS, Neale MC, MacLean CJ et al (1993) Smoking and major depression: a casual analysis. Arch Gen Psychiatry 50:36–43

    Article  PubMed  CAS  Google Scholar 

  104. Kenford SL, Smith SS, Wetter DW et al (2002) Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70:216–227

    Article  PubMed  Google Scholar 

  105. Keyler DE, Roiko SA, Earley CA et al (2008) Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 8:1589–1594

    Article  PubMed  CAS  Google Scholar 

  106. Killen JD, Fortmann SP, Kraemer HC et al (1996) Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse. J Consult Clin Psychol 64:1060–1067

    Article  PubMed  CAS  Google Scholar 

  107. Kinnunen T, Doherty K, Militello FS et al (1996) Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol 64:791–798

    Article  PubMed  CAS  Google Scholar 

  108. Kollins SH, McClernon FJ, Fuemmeler BF (2005) Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 62:1142–1147

    Article  PubMed  Google Scholar 

  109. Koob GF (1999) Stress, corticotropin-releasing factor, and drug addiction. Ann NY Acad Sci 897:27–45

    Article  PubMed  CAS  Google Scholar 

  110. Lasser K, Boyd JW, Woolhandler S et al (2000) Smoking and mental illness: a population-based prevalence study. JAMA 2284:2606–2610

    Article  Google Scholar 

  111. Le FB, Forget B, Aubin HJ et al (2008) Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 13:239–252

    Article  CAS  Google Scholar 

  112. Lerman C, Shields PG, Audrain J et al (1998) The role of the serotinin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prev 7:253–255

    PubMed  CAS  Google Scholar 

  113. Lerman C, Caporaso NE, Audrain J et al (1999) Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18:14–20

    Article  PubMed  CAS  Google Scholar 

  114. Lerman C, Shields PG, Wileyto EP et al (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22:541–548

    Article  PubMed  Google Scholar 

  115. Lerman C, Wileyto EP, Patterson F (2004) The funtional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4:184–192

    Article  PubMed  CAS  Google Scholar 

  116. Lerman C, Jepson C, Wileyto EP et al (2006) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31:231–242

    PubMed  CAS  Google Scholar 

  117. Lessov-Schlaggar CN, Pergadia ML, Khroyan TV et al (2008) Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol 75:178–195

    Article  PubMed  CAS  Google Scholar 

  118. Li MD (2008) Identifying susceptibility loci for nicotine dependence: 2008 update based on recent genome-wide linkage analyses. Human Genetics 123:119–131

    Article  PubMed  CAS  Google Scholar 

  119. Lowinson JH, Ruiz P, Millman RB et al (2005) Substance abuse: a comprehensive textbook. Lippincott Williams & Wilkins, New York

    Google Scholar 

  120. Lubman DI, Yucel M, Pantelis C (2004) Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction 99:1491–1502

    Article  PubMed  Google Scholar 

  121. Maurer P, Bachmann MF (2007) Vaccination against nicotine: an emerging therapy for tobacco dependence Expert Opin Investig Drugs 16:1775–1783

    Article  PubMed  CAS  Google Scholar 

  122. Maurer P, Jennings GT, Willers J et al (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35: 2031–2040

    Article  PubMed  CAS  Google Scholar 

  123. McNair DM, Lorr M, Droppleman LF (1992) Profile of mood states manual. Education and Industrial Testing Service, San Diego, CA

    Google Scholar 

  124. Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at {alpha}4beta2 and a full agonist at {alpha}7 neuronal nicotinic receptors. Mol Pharmacol 70:801–805

    Article  PubMed  CAS  Google Scholar 

  125. Mooney ME, Sofuoglu M (2006) Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother 6:965–981

    Article  PubMed  CAS  Google Scholar 

  126. Morris S, Mermelstein R (1999) Depression and relapse: antecedent or consequence? Presented at the 5th annual meeting of the society for research on nicotine and tobacco, March 1999, San Diego, CA

    Google Scholar 

  127. Munafo MR, Flint J (2004) Meta-analysis of genetic association studies. Trends Genet 20:439–444

    Article  PubMed  CAS  Google Scholar 

  128. Munafo MR, Johnstone EC (2008) Genes and cigarette smoking. Addiction 103:893–904

    Article  PubMed  Google Scholar 

  129. Munafo M, Clark T, Johnstone E et al (2004) The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 6:583–597

    Article  PubMed  CAS  Google Scholar 

  130. Murray RL, Coleman T, Antoniak M et al (2008) The effect of proactively identifying smokers and offering smoking cessation support in primary care populations: a cluster-randomized trial. Addiction 103:998–1006

    Article  PubMed  Google Scholar 

  131. National Institute on Drug Abuse (2008) The neurobiology of drug addiction. NIDA Notes. Available at: http://www.nida.nih.gov/pubs/teaching/Teaching2/Teaching.html, Accessed June 2010

  132. Neuhaus A, Bajbouj M, Kienast T et al (2006) Persistent dysfunctional frontal lobe activation in former smokers. Psychopharmacology (Berl) 186:191–200

    Article  CAS  Google Scholar 

  133. Niaura R, Britt DM, Borrelli B et al (1991) History and symptoms of depression among smokers during a self-initiated quit attempt. Nicotine Tob Res 1:251–257

    Article  Google Scholar 

  134. Nielsen K, Petersen SE, Orntoft T (1989) A comparison between stereological estimates of mean nuclear volume and DNA flow cytometry in bladder tumours. APMIS 97:949–956

    Article  PubMed  CAS  Google Scholar 

  135. Nisell M, Marcus M, Nomikos GG (1997) Differential effects of acute and chronic nictoine on dopamine output in the core and shell of the rat nucleus accumbens. J Neural Transm 104:1–10

    Article  PubMed  CAS  Google Scholar 

  136. Nomikos GG, Damsma G, Wenkstern D et al (1989) Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2:273–279

    Article  PubMed  CAS  Google Scholar 

  137. O’Connor PG, Fiellin DA (2000) Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 133:40–54

    PubMed  Google Scholar 

  138. Payne TJ, Smith PO, McCracken LM et al (1994) Assessing nicotine dependence: a comparison of the Fagerström tolerance questionnaire (FTQ) with the Fagerström test for nicotine dependence (FTND) in a clinical sample. Addict Behav 19:307–374

    Article  PubMed  CAS  Google Scholar 

  139. Pentel PR, Malin DH, Ennifar S et al (2000) A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65:191–198

    Article  PubMed  CAS  Google Scholar 

  140. Piasecki TM, Jorenby DE, Smith SS et al (2003) Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers. J Abnorm Psychol 112:3–13

    Article  PubMed  Google Scholar 

  141. Piasecki TM, Jorenby DE, Smith SS et al (2003) Smoking withdrawal dynamics: III. Correlates of withdrawal heterogeneity. Exp Clin Psychopharmacol 11:276–285

    Article  PubMed  Google Scholar 

  142. Picciotto MR, Zoli M, Rimondini R et al (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173–177

    Article  PubMed  CAS  Google Scholar 

  143. Pidoplichko VI, DeBiasi M, Williams JT et al (1997) Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390:401–404

    Article  PubMed  CAS  Google Scholar 

  144. Piper ME, Piasecki TM, Federman EB et al (2004) A multiple motives approach to tobacco dependence: the Wisconsin inventory of smoking dependence motives (WISDM-68). J Consult Clin Psychol 72:139–154

    Article  PubMed  Google Scholar 

  145. Poling J, Oliveto A, Petry N et al (2006) Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 63:219–28

    Article  PubMed  CAS  Google Scholar 

  146. Pomerleau CS, Pomerleau OF, Majchrzak MJ et al (1990) Relationship between Fagerström tolerance questionnaire scores and plasma cotinine. Addict Behav 15:73–80

    Article  PubMed  CAS  Google Scholar 

  147. Pontieri FE, Tanda G, Orzi F et al (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382:255–257

    Article  PubMed  CAS  Google Scholar 

  148. Raichle ME, Fiez JA, Videen TO et al (1994) Practice-related changes in human brain functional anatomy during nonmotor learning. Cereb Cortex 4:8–26

    Article  PubMed  CAS  Google Scholar 

  149. Robinson TE, Berridge KC (2001) Incentive-sensitization and addiction. Addiction 96:103–114

    Article  PubMed  CAS  Google Scholar 

  150. Robinson TE, Berridge KC (2008) Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 363:3137–3146

    Article  PubMed  Google Scholar 

  151. Robinson TE, Gorny G, Mitton E et al (2001) Cocaine self-administration alters the morphology of dendrites and dendritic spines in the nucleus accumbens and neocortex. Synapse 39:257–266

    Article  PubMed  CAS  Google Scholar 

  152. Sabol SZ, Nelson ML, Fisher C et al (1999) A genetic association for cigarette smoking behavior. Health Psychol 18:7–13

    Article  PubMed  CAS  Google Scholar 

  153. Saccone SF, Hinrichs AL, Saccone NL et al (2007) Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3,713 SNPs. Hum Mol Genet 16:36–49

    Article  PubMed  CAS  Google Scholar 

  154. Sarnyai Z (1998) Neurobiology of stress and cocaine addiction. Studies on corticotropin-releasing factor in rats, monkeys, and humans. Ann NY Acad Sci 851:371–387

    Article  PubMed  CAS  Google Scholar 

  155. Seidman LJ, Biederman J, Faraone SV et al (1997) Toward defining a neuropsychology of attention deficit-hyperactivity disorder: performance of children and adolescents from a large clinically referred sample. J Consult Clin Psychol 65:150–160

    Article  PubMed  CAS  Google Scholar 

  156. Shiffman S, Paty J, Gnys M et al (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64:366–379

    Article  PubMed  CAS  Google Scholar 

  157. Silagy C, Lancaster T, Stead L et al (2004) Nicotine replacement therapy for smoking cessation. Report No. 3. Wiley, Chichester, UK

    Google Scholar 

  158. Slemmer JE, Martin BP, Damaj I (2000) Bupropion is a nicotine antagonist. J Pharmacol Exp Ther 295:321–327

    PubMed  CAS  Google Scholar 

  159. Smith SS, Jorenby DE, Leischow SJ et al (2003) Targeting smokers at increased risk for relapse: treatming women and those with a history of depression. Nicotine Tob Res 5:99–109

    Article  PubMed  Google Scholar 

  160. Spitz MR, Shi H, Hudmon KS et al (1998) A case-control study of the dopamine D2 receptor gene and smoking status in lung cancer. J Natl Cancer Inst 90:358–363

    Article  PubMed  CAS  Google Scholar 

  161. Spitz MR, Amos CI, Dong Q et al (2008) The CHRNA5-A3 region on chromosome 15q24–25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst 100:1552–1556

    Article  PubMed  CAS  Google Scholar 

  162. Straub RE, Sullivan PF, Ma Y et al (1999) Susceptibility genes for nicotine dependence: a genome scan and followup in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17, and 18 merit further study. Mol Psychiatry 4:129–144

    Article  PubMed  CAS  Google Scholar 

  163. Stuss DT, Gow CA, Hetherington CR (1992) “No longer Gage”: frontal lobe dysfunction and emotional changes. J Consult Clin Psychol 60:349–359

    Article  PubMed  CAS  Google Scholar 

  164. Substance Abuse and Mental Health Services Administration (2008) Results from the 2007 national survey on drug use and health: national findings. Report No. DHHS Publication No. SMA 08–4343, DHHS, Rockville, MD

    Google Scholar 

  165. Swan GE, Valdes AM, Ring HZ et al (2005) Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 5:21–29

    Article  PubMed  CAS  Google Scholar 

  166. Tapert SF, Baratta MV, Abrantes AM et al (2002) Attention dysfunction predicts substance involvement in community youths. J Am Acad Child Adolesc Psychiatry 41:680–686

    Article  PubMed  Google Scholar 

  167. Thorgeirsson TE, Geller F, Sulem P et al (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452:638–642

    Article  PubMed  CAS  Google Scholar 

  168. Tonstad S, Hays JT, Jorenby DE et al (2005) Varenicline phase III studies. Poster presentation at the American Heart Association 2005 Scientific Sessions

    Google Scholar 

  169. Tonstad S, Tonnesen P, Hajek P et al (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296:64–71

    Article  PubMed  CAS  Google Scholar 

  170. Torregrossa MM, Kalivas PW (2008) Microdialysis and the neurochemistry of addiction. Pharmacol Biochem Behav 90:261–272

    Article  PubMed  CAS  Google Scholar 

  171. Torrens M, Fonseca F, Mateu G et al (2005) Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Dependence 78:1–22

    Article  CAS  Google Scholar 

  172. True WR, Heath AC, Scherrer JF et al (1997) Genetic and environmental contributions to smoking. Addiction 92:1277–1287

    Article  PubMed  CAS  Google Scholar 

  173. Tsoh JY, Cinciripini PM, Wetter D et al (1999) Depression history, negative affect, and stages of change in smoking cessation. Ann Beh Med 21(Suppl):205

    Google Scholar 

  174. Tutka P, Zatonski W (2006) Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 58:777–798

    PubMed  CAS  Google Scholar 

  175. Ueda H (2004) Anti-opioid systems in morphine tolerance and addiction—locus-specific involvement of nociceptin and the NMDA receptor. Novartis Found Symp 261:155–162

    Article  PubMed  CAS  Google Scholar 

  176. Uhl GR, Liu QR, Drgon T et al (2007) Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genet 8:10

    Article  PubMed  CAS  Google Scholar 

  177. Uhl GR, Liu QR, Drgon T et al (2008) Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 65:683–693

    Article  PubMed  CAS  Google Scholar 

  178. U.S. Department of Health and Human Services (2000) Reducing tobacco use: a report of the surgeon general. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Centers for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA

    Google Scholar 

  179. U.S. Food and Drug Administration. (2008) Public health advisory, important information on chantix (varenicline). Department of Health and Human Services, Rockville, MD

    Google Scholar 

  180. Volkow ND, Fowler J, Wang G-J (2002) Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 13:355–366

    Article  PubMed  CAS  Google Scholar 

  181. Volkow ND, Fowler JS, Wang GJ (2004) The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47(Suppl 1):3–13

    Article  PubMed  CAS  Google Scholar 

  182. Wagena EJ, de Vos A, Horwith G et al (2008) The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res 10:213–218

    Article  PubMed  CAS  Google Scholar 

  183. Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS Scales. J Personal Soc Psychol 54:1063–1070

    Article  CAS  Google Scholar 

  184. Wennike P, Danielsson T, Landfeldt B et al (2003) Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 98:1395–1402

    Article  PubMed  Google Scholar 

  185. Wetter DW, Smith SS, Kenford SL et al (1994) Smoking outcome expectancies: factor structure, predictive validity, and discriminant validity. J Abnorm Psychol 103:801–811

    Article  PubMed  CAS  Google Scholar 

  186. Wetter DW, Kenford SL, Smith SS et al (1999) Gender differences in smoking cessation. J Consult Clin Psychol 67:555–562

    Article  PubMed  CAS  Google Scholar 

  187. Wilens TE, Biederman J (2006) Alcohol, drugs, and attention-deficit/hyperactivity disorder: a model for the study of addictions in youth. J Psychopharmacol 4:580–588

    Article  Google Scholar 

  188. Williams JM, Ziedonis D (2004) Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 29:1067–1083

    Article  PubMed  Google Scholar 

  189. Xu J, Mendrek A, Cohen MS et al (2005) Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence. Biol Psychiatry 58:143–150

    Article  PubMed  CAS  Google Scholar 

  190. Yudkin P, Munafo M, Hey K et al (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328:989–990

    Article  PubMed  Google Scholar 

  191. Zhang H, Ye Y, Wang X et al (2006) DOPA decarboxylase gene is associated with nicotine dependence. Pharmacogenomics 7:1159–1166

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Behavioral Science, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA

    Maher Karam-Hage, Jennifer Minnix & Paul M. Cinciripini

Authors
  1. Maher Karam-Hage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Minnix
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul M. Cinciripini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maher Karam-Hage .

Editor information

Editors and Affiliations

  1. , Depts Psychiat & Neurobehav Sciences, Me, University of Virginia, Charlottesville, 22908, Virginia, USA

    Bankole A. Johnson

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Karam-Hage, M., Minnix, J., Cinciripini, P.M. (2010). Nicotine. In: Johnson, B. (eds) Addiction Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0338-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0338-9_19

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-0337-2

  • Online ISBN: 978-1-4419-0338-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation